Bristol Myers Squibb Company $BMY Stock Purchased by Candriam S.C.A.

Candriam S.C.A. grew its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 2.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,223,695 shares of the biopharmaceutical company’s stock after acquiring an additional 27,623 shares during the quarter. Candriam S.C.A. owned about 0.06% of Bristol Myers Squibb worth $76,638,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Lazard Asset Management LLC raised its stake in Bristol Myers Squibb by 23.7% during the 1st quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock valued at $116,693,000 after buying an additional 368,193 shares during the last quarter. Callan Family Office LLC purchased a new position in shares of Bristol Myers Squibb in the 2nd quarter worth $3,575,000. Saudi Central Bank boosted its stake in shares of Bristol Myers Squibb by 90.2% in the 2nd quarter. Saudi Central Bank now owns 142,922 shares of the biopharmaceutical company’s stock worth $8,235,000 after buying an additional 67,780 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after acquiring an additional 8,702,106 shares during the period. Finally, Envestnet Asset Management Inc. grew its holdings in shares of Bristol Myers Squibb by 17.4% in the second quarter. Envestnet Asset Management Inc. now owns 2,142,754 shares of the biopharmaceutical company’s stock worth $123,465,000 after acquiring an additional 317,360 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Insiders Place Their Bets

In other news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Julia A. Haller sold 3,800 shares of the stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $63.31, for a total value of $240,578.00. Following the sale, the director owned 30,279 shares of the company’s stock, valued at approximately $1,916,963.49. This represents a 11.15% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.05% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on BMY shares. Wells Fargo & Company lowered their target price on Bristol Myers Squibb from $65.00 to $60.00 and set an “equal weight” rating on the stock in a report on Tuesday, October 13th. Daiwa Securities Group raised their target price on Bristol Myers Squibb from $53.00 to $66.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. Sanford C. Bernstein restated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 13th. Weiss Ratings raised shares of Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. Finally, Argus upgraded shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price objective on the stock in a research note on Wednesday, August 5th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $65.46.

Bristol Myers Squibb Stock Down 1.5%

NYSE BMY opened at $62.20 on Friday. Bristol Myers Squibb Company has a 12 month low of $45.26 and a 12 month high of $68.64. The company has a current ratio of 1.59, a quick ratio of 1.44 and a debt-to-equity ratio of 1.79. The stock has a market cap of $127.15 billion, a PE ratio of 13.79, a P/E/G ratio of 0.32 and a beta of 0.20. The stock’s 50 day moving average is $62.34 and its 200 day moving average is $60.11.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.10 by $0.25. The company had revenue of $13.07 billion for the quarter, compared to the consensus estimate of $12.72 billion. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The firm’s revenue was up 6.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.63 EPS. Research analysts predict that Bristol Myers Squibb Company will post 6.45 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.1%. The ex-dividend date of this dividend was Friday, October 2nd. Bristol Myers Squibb’s payout ratio is currently 55.88%.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported 56-week Phase 3 results for Camzyos (mavacamten) in children with symptomatic obstructive hypertrophic cardiomyopathy. Sustained efficacy could support the drug’s potential in a broader patient population, though the report does not say that pediatric use has been approved. Article: Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
• Positive Sentiment: A multi-year AI alliance expands the company’s neuroscience efforts, potentially supporting future drug discovery, although the supplied report gives no financial terms or near-term revenue outlook. Article: Bristol Myers Squibb Expands Neuroscience Push With Multi Year AI Alliance
• Positive Sentiment: Recent coverage also highlighted FDA accelerated approval for ZENBEXUS in multiple myeloma and positive trial updates in other diseases. These developments add to the pipeline narrative, though investors may weigh how much expected optimism is already reflected in the shares. Article: Bristol Myers Squibb Wins FDA Approval
• Neutral Sentiment: A company director disclosed selling 3,800 shares. Insider sales can attract attention, but the filing alone does not establish the director’s reason or signal a change in the company’s outlook. SEC Form 4 filing
• Negative Sentiment: A dividend-focused article flags potential pressure from an expected $1.5 billion–$2 billion decline in blood-thinner sales and the company’s debt burden. That raises questions about dividend sustainability, though the article does not establish that a cut is imminent. Article: Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.

The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.